Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $1,330.0 million
Deal Type : Collaboration
Kumquat Biosciences Partners with Takeda On Oral Immuno-Oncology Drug
Details : Kumquat granted Takeda a global license to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono- or combination-therapy.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $130.0 million
April 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Takeda Pharmaceutical
Deal Size : $1,330.0 million
Deal Type : Collaboration
Lilly and Kumquat Biosciences Discover and Develop Novel Small Molecules
Details : Kumquat will utilize its small molecule immuno-oncology platform to discover novel clinical candidates and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldwide, excluding Greater China...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $70.0 million
July 29, 2021
LOOKING FOR A SUPPLIER?